SABS (STOCKS)
SAB Biotherapeutics, Inc. Common Stock
$4.130000
-0.050000 (-1.20%)
Prev close: $4.180000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Samuel J. Reich
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $196.38M
- Employees
- 63
- P/E (TTM)
- -1.33
- P/B (TTM)
- 1.19
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.15 | $-0.52 | +0.3661 | +70.94% |
|
Jun 2025 (Q2)
|
$-1.09 | $-0.81 | -0.2781 | -34.25% |
|
Mar 2025 (Q1)
|
$-0.56 | $-1.05 | +0.4906 | +46.70% |
|
Dec 2024 (Q4)
|
$-1.23 | $-1.19 | -0.0387 | -3.26% |
Financial Statements
| Revenues | $114.70K |
| Nonoperating Income/Loss | $61.93M |
| Operating Expenses | $43.31M |
| Research and Development | $31.28M |
| Other Operating Expenses | $12.03M |
| Operating Income/Loss | -$43.19M |
| Income/Loss From Continuing Operations After Tax | $18.74M |
| Income/Loss From Continuing Operations Before Tax | $54.17M |
| Net Income/Loss | $18.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $18.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$21.37M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $80.22M |
| Preferred Stock Dividends And Other Adjustments | $40.11M |
| Basic Earnings Per Share | -$2.38 |
| Diluted Earnings Per Share | -$3.09 |
| Basic Average Shares | 29,256,433 |
| Diluted Average Shares | 87,166,104 |
| Assets | $183.45M |
| Current Assets | $113.28M |
| Noncurrent Assets | $70.17M |
| Fixed Assets | $13.11M |
| Other Non-current Assets | $57.06M |
| Liabilities | $18.37M |
| Current Liabilities | $10.79M |
| Accounts Payable | $2.95M |
| Wages | $3.71M |
| Other Current Liabilities | $4.13M |
| Noncurrent Liabilities | $7.58M |
| Equity | $165.07M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $165.07M |
| Liabilities And Equity | $183.45M |
| Net Cash Flow From Operating Activities | -$37.53M |
| Net Cash Flow From Operating Activities, Continuing | -$37.53M |
| Net Cash Flow From Investing Activities | -$110.67M |
| Net Cash Flow From Investing Activities, Continuing | -$110.67M |
| Net Cash Flow From Financing Activities | $168.56M |
| Net Cash Flow From Financing Activities, Continuing | $168.56M |
| Net Cash Flow | $20.36M |
| Net Cash Flow, Continuing | $20.36M |
| Comprehensive Income/Loss | $18.64M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $18.76M |
| Other Comprehensive Income/Loss | $33.95M |